Castle Biosciences(US:CSTL) Globenewswire·2025-11-03 21:07Financial Performance - Company reported Q3 2025 revenue of $83 million, a decrease from $85.8 million in Q3 2024 [5][9] - Non-dermatologic revenue increased by 67% compared to Q3 2024 [1] - Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 36% over Q3 2024 [1] - Company raised full-year 2025 revenue guidance to $327-335 million from $310-320 million [1][8] Operational Highlights - Total test reports delivered in Q3 2025 were 26,841, compared to 26,010 in Q3 2024 [5] - DecisionDx-Melanoma test reports delivered were 10,459, up from 9,367 in Q3 2024 [5] - TissueCypher Barrett's Esophagus test reports delivered were 10,609, compared to 6,073 in Q3 2024 [5] - DecisionDx-SCC test reports delivered were 4,186, slightly down from 4,195 in Q3 2024 [5] New Product Launch - Company announced the launch of AdvanceAD-Tx™, a test designed to guide systemic treatment decision-making in patients with moderate-to-severe atopic dermatitis [1][12] Gross Margin and Adjusted Metrics - Gross margin for Q3 2025 was 75%, down from 79% in Q3 2024 [5] - Adjusted gross margin was 77%, compared to 82% in the same period of 2024 [5] - Adjusted EBITDA for Q3 2025 was $9.2 million, down from $21.6 million in Q3 2024 [9] Cash and Investments - As of September 30, 2025, the company's cash, cash equivalents, and marketable investment securities totaled $287.5 million [7]